Skip to content


Slynd, Drovelis, Lydisilka (drospirenone) is a small molecule pharmaceutical. Drospirenone was first approved as Slynd on 2019-05-23. It has been approved in Europe to treat contraception. The pharmaceutical is active against mineralocorticoid receptor. Yasmin's patent is valid until 2031-06-28 (FDA).
Trade Name Drovelis, Lydisilka
Common Name Drospirenone
Indication contraception
Drug Class Aldosterone antagonists (spironolactone type)
Get full access now